Forte Biosciences 過去の業績

NasdaqCM:FBRX 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Sep 24	-34	16	20
30 Jun 24	-36	17	20
31 Mar 24	-32	12	21
31 Dec 23	-31	11	22
30 Sep 23	-30	10	21
30 Jun 23	-24	8	16
31 Mar 23	-18	9	10
31 Dec 22	-14	8	6
30 Sep 22	-12	8	4
30 Jun 22	-17	8	9
31 Mar 22	-19	8	11
31 Dec 21	-22	8	14
30 Sep 21	-23	7	16
30 Jun 21	-20	6	14
31 Mar 21	-49	5	12
31 Dec 20	-46	4	10
30 Sep 20	-43	3	8
30 Jun 20	-39	2	5
31 Mar 20	-5	2	3
31 Dec 19	-4	1	3

質の高い収益: FBRXは現在利益が出ていません。

利益率の向上: FBRXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: FBRXは利益が出ておらず、過去 5 年間で損失は年間3.9%の割合で増加しています。

成長の加速: FBRXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: FBRXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: FBRXは現在利益が出ていないため、自己資本利益率 ( -365.1% ) はマイナスです。

Forte Biosciences 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Forte Biosciences, Inc. to Report Q4, 2020 Results on Mar 24, 2021

Forte Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Forte Biosciences, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Recent updates

Forte Biosciences, Inc. announced that it expects to receive $53 million in funding from OrbiMed Advisors LLC, Janus Henderson Group plc, Tybourne Capital Management Limited, Ikarian Capital, LLC, BVF Partners L.P., Fred Alger Management, LLC

High number of new directors

High number of new directors

New major risk - Market cap size

New major risk - Share price stability

Price target increased by 25% to US$4.38

Forte Biosciences, Inc., Annual General Meeting, Aug 20, 2024

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

New minor risk - Share price stability

New major risk - Financial position

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New major risk - Financial position

High number of new directors

Forte Biosciences Receives Non-Compliance Letter from Nasdaq

Camac Partners Shares Key Facts that Reinforce the Need for Urgent Change in Forte Biosciences’s Boardroom

Forte Biosciences, Inc., Annual General Meeting, Sep 19, 2023

New major risk - Shareholder dilution

Forte Biosciences, Inc appoints David Gryska to the Board of Directors

CEO & Chairman recently bought US$105k worth of stock

High number of new and inexperienced directors

Forte Biosciences, Inc. Announces Dr. Scott Brun to Its Board of Directors

Cable Car Capital Expects Response of Forte Biosciences for its Concerns

Cable Car Capital Waiting for the Response of Forte Biosciences

Cable Car Capital Sends Letter to the Board of Forte Biosciences

Large Forte Biosciences shareholder scolds company board of directors

Camac Partners, LLC Urges the Board to Reverse Course and Return Capital to Shareholders

Camac Partners, LLC Urges the Board to Reverse Course and Return Capital to Shareholders

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Forte Biosciences large shareholders make demands for company's future

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

BML Capital Management Sends an Email to Chairman & CEO of Forte Biosciences

Forte Biosciences, Inc. Appoints Stephen K. Doberstein to its Board

Forte Biosciences, Inc., Annual General Meeting, Jun 01, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

High number of new and inexperienced directors

President recently sold US$4.3m worth of stock

Price target increased to US$103

Director Thomas Darcy has left the company

Forte Biosciences files for $300M mixed shelf offering

Forecast to breakeven in 2025

Forte Biosciences, Inc. Expects to Report the Topline Results from That Trial in the Third Quarter of 2021

Forte Biosciences, Inc. to Report Q4, 2020 Results on Mar 24, 2021

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

New 90-day low: US$30.76

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 2000 Dynamic Index

New 90-day low: US$33.73

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Forte Biosciences readies equity offering

Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis

Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults with Atopic Dermatitis

New 90-day high: US$50.69

Forte Biosciences, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell Small Cap Completeness Index

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 3000 Index

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 2500 Growth Index

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06